Gilbert Technologies, which is developing a soft mist inhaler device based on electrohydrodynamic atomization technology, announced that Scott Fleming will take on the role of Chief Commercial Officer. Fleming, who has been the company’s Technology Director for the past two years, has extensive experience in OINDPs. A co-founder of inhaled drug developer Microdose Therapeutx, Fleming served as Senior Director Global Respiratory and eConnectivity at Teva after the acquisition of Microdose Therapeutx by Teva in 2013. In 2017, he joined inhaler sensor company Adherium as Senior Director of Business Development, Europe.
Gilbert Technologies CEO Maurits Huigen said, “For the last three years, we have worked closely with Scott on the development of our technology making substantial progress on the development of our first prototype, and preparing the foundation for the development of our clinical device. We are privileged to name him Chief Commercial Officer as we continue our progress towards our mission to redefine treatment for lung patients with difficult to treat conditions. Scott’s broad experience will play a pivotal role in getting to key inflection points on the development of our clinical device and our partnerships with pharmaceutical companies.”
Fleming commented, “I am excited to continue my journey with the Gilbert team as CCO. I have been very impressed by the potential the electrospray technology offers to deliver more advanced pulmonary drugs (large and small molecules) in a targeted way to patients by inhalation, making treatments safer and more effective. Chronic lung diseases remain the third leading cause of death and disability worldwide. This drives me to deliver on the promise of our mission to make medical treatment easier and more effective, to save lives and help patients live the life they want, while reducing the burden on our healthcare systems.”
Read the Gilbert Technologies press release.
